These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 23104975)

  • 1. Academic investigator-initiated trials and the challenge of sponsor responsibility: the Cologne Sponsor Model.
    Georgias C; Grunow A; Olderog M; May A; Paulus U
    Clin Trials; 2012 Dec; 9(6):781-7. PubMed ID: 23104975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Non-commercial clinical trials--who will be the legal sponsor? Sponsorship of investigator-initiated clinical trials according to the German Drug Law].
    Benninger-Döring G; Boos J
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2006 Jul; 49(7):675-80. PubMed ID: 16763801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The 12th amendment to the German Drug Law. Chances and obstacles for investigator-initiated clinical trials].
    Dreier G; Marx C; Schmoor C; Maier-Lenz H
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Apr; 48(4):445-52. PubMed ID: 15830256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [ICH-GCP Guideline: quality assurance of clinical trials. Status and perspectives].
    Englev E; Petersen KP
    Ugeskr Laeger; 2003 Apr; 165(16):1659-62. PubMed ID: 12756823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [New Japanese GCP--from the standpoint of a sponsor].
    Ebi O
    Gan To Kagaku Ryoho; 1998 Apr; 25(5):650-62. PubMed ID: 9571962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Implementation of new Japanese GCP and the quality of clinical trials--from the standpoint of the pharmaceutical industry].
    Ebi O
    Gan To Kagaku Ryoho; 1997 Oct; 24(13):1883-91. PubMed ID: 9350232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Experience as a model hospital for new good clinical practice (GCP) regulations].
    Tanaka S
    Gan To Kagaku Ryoho; 1998 Aug; 25(10):1467-73. PubMed ID: 9725036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Recording and reporting adverse reactions in clinical trials. New legal provisions according to the 12th Law Amending the German Drug Law (AMG) and the Ordinance on GCP (GCP-V)].
    Eckhardt K; Cremer-Schaeffer P; König J; Paeschke N
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Feb; 48(2):173-80. PubMed ID: 15726458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effects of the 12th amendment to the German drug code on investigator-initiated clinical trials].
    Kehrel U
    Gesundheitswesen; 2011 Oct; 73(10):696-701. PubMed ID: 20859850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The GCP directive--consequences for clinical drug research].
    Gluud CN
    Ugeskr Laeger; 2003 Apr; 165(16):1662-4. PubMed ID: 12756824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Mission and tasks of the Coordination Centres for Clinical Trials].
    Luntz SP; Gorbauch T; Schröder B; Seibert-Grafe M
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2009 Apr; 52(4):444-50. PubMed ID: 19263026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Good clinical practices in clinical trials: the responsibility of the researcher. A survey of 827 hospital physicians (I). Availability. Monitoring. Safety. Contract].
    Dal-Ré R
    Med Clin (Barc); 1993 Mar; 100(9):346-50. PubMed ID: 8455413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Consequences of the 12th AMG amendment on the conduct of non-commercial clinical trials].
    Rossion I
    Urologe A; 2005 Dec; 44(12):1444-8. PubMed ID: 16283155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges for academic investigator-initiated pediatric trials for rare diseases.
    Ahmed R; Duerr U; Gavenis K; Hilgers R; Gross O
    Clin Ther; 2014 Feb; 36(2):184-90. PubMed ID: 24529291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical trials integrity: a CRO perspective.
    Beach JE
    Account Res; 2001; 8(3):245-60. PubMed ID: 12481762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The NCI All Ireland Cancer Conference.
    Johnston PG; Daly PA; Liu E
    Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and quality in clinical trials. Requirements to the investigator site. European Economic Community.
    Friederichs E; Spitzer SG; Bach R
    Arzneimittelforschung; 1994 Feb; 44(2):182-4. PubMed ID: 8147953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Focus on academic multicenter trials: impact of the German drug law on hematological/oncological therapy optimization trials].
    Ihrig K; Fath B; Fuchs M; Hallek M; Marschner N; Naumann R; Röllig C; Saussele S; Tesch H; Gökbuget N
    Onkologie; 2013; 36 Suppl 2():23-8. PubMed ID: 23549033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Objectives of QC systems and QA function in clinical research.
    Poy E
    Qual Assur; 1993 Dec; 2(4):326-31. PubMed ID: 7952966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Operation of a radiopharmacy for a clinical trial.
    Norenberg JP; Petry NA; Schwarz S
    Semin Nucl Med; 2010 Sep; 40(5):347-56. PubMed ID: 20674594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.